Search Results

BioMarin Pharmaceutical Inc. will be presented at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Bangkok, Thailand, June 22-26, 2024.

Poseida Therapeutics, Inc. today announced that two abstracts have been accepted for presentation at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH), being held in Montreal, Canada and virtually on June 24-28, 2023.

Hemab Therapeutics announced it will present data from preclinical research of HMB-001 in Factor VII deficiency at the upcoming International Society on Thrombosis and Haemostasis 2023 Congress, June 24 – 28, in Montreal.

Rallybio Corporation announced that an abstract for RLYB212 reporting results from the Phase 1b proof-of-concept study has been accepted for presentation at the 31st Congress of the International Society on Thrombosis and Haemostasis, which will take place in Montreal from June 24-28.

Rallybio Corporation (Nasdaq: RLYB) today announced that results from the RLYB212 Phase 1b proof-of-concept study will be presented at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH), which will take place in Montreal from June 24-28.

The International Society on Thrombosis and Haemostasis announces that all ISTH 2024 Congress abstracts are available online, including late-breakthrough abstracts, to give a detailed glimpse into the posters, presentations and plenaries that will be presented at the Congress in Bangkok, Thailand.

VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), in collaboration with researchers at the University of Namur and QUALIblood in Belgium has published a poster presentation entitled “Evaluation and comparison of NETosis biomarkers in sepsis and COVID-19 patients” at the International Society on Thrombosis and Haemostasis (ISTH) Congress earlier this week.